AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...
Contract manufacturing powerhouse Lonza is growing in more ways than one. | Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is ...
Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares are among the seven ...
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. | After a site visit by FDA ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key ...
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...
The FDA has issued a complete response letter to Unicycive over the “same third-party manufacturing deficiencies that were ...
Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...
Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...
Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results